Our Stories
Keyword Search
.png?width=700&height=700&ext=.png){kind=logo}
Marking Women's Equality Day
Hear from three female senior leaders as they offer perspectives on our commitment to gender equality.
Learning from Patients: Our Commitment to the Narcolepsy Community
Hear from Craig Hopkinson, M.D. as he reflects on the unmet needs of people living with narcolepsy.
Alkermes in Action
This year, we’re celebrating 15 years of “Alkermes in Action,” our employee-led volunteer program that supports local non-profit organizations through hands-on activities.
Alkermes Celebrates Pride
Throughout June, Team Alkermes celebrated Pride Month with events hosted by Pride@Work, our ERG for LGBTQ+ employees and allies.
Commitment to Equality
See what our valued co-leaders have to say about our ERG for LGBTQ+ employees and allies.
HBA Rising Star 2023
We’re proud to recognize Swetha Krishnan, Senior Director of Quality, as our 2023 Healthcare Businesswomen’s Association (HBA) Rising Star – a testament to her leadership and commitment to excellence.
Cultivating a Healthy Workplace
Hear from Steve Schiavo on Alkermes' commitment to being a recovery-friendly workplace.
Showcasing Alkermes’ Commitment to the Sleep Community
Hear from Markus Haeberlein, Ph.D. where he discusses our commitment to researching potential treatment options for people living with sleep disorders.
Embracing Diversity at Alkermes
This Women’s History Month, we celebrate the accomplishments of the many women making a difference at Alkermes. Meet the co-leads of Mosaic, our ERG dedicated to multicultural diversity.
Seeking to Fill Cancer Treatment Gaps
Hear from Dr. Craig Hopkinson in this PharmaVoice article where he discusses our commitment to developing novel potential therapies for people living with difficult-to-treat cancers.
Honoring the Sacrifice
Hear from leaders of Operation Salute, our ERG dedicated to recognizing and supporting veterans and their family members.
Building A Welcoming Workplace for All
Hear from leaders of Limitless, our ERG dedicated to empowering those whose lives are impacted by disability or illness.
Psychiatrist Perspectives
Alkermes worked with The Harris Poll to gather psychiatrists’ insights and perspectives on caring for people living with bipolar I disorder.
HBA Luminary 2022
Congratulations to Kanchan Relwani, M.D., Head of Medical Affairs, for being recognized as our 2022 Healthcare Businesswomen’s Association Luminary – a testament to her role as a mentor and leader.
Cancer Trials At-a-Glance
Learn more about our ongoing clinical development program for nemvaleukin alfa, our lead immuno-oncology candidate.
Our Pursuit of Progress
Alkermes' Head of Human Resources Steve Schiavo reflects on our employees' commitment during the COVID-19 pandemic.
Unlocking IL-2's Potential
As the unmet medical need in oncology changes, Alkermes is using its R&D capabilities honed over 30 years of work on complex diseases to investigate a potential next breakthrough in cancer therapy.
Alkermes Gives Back
Alkermes employees seek to make a positive impact in their communities by taking part in Alkermes in Action, our employee-led volunteer program that represents our commitment to giving back to our loc
Pandemic Drinking Habits
Alkermes worked with The Harris Poll to conduct a survey exploring drinking patterns during the COVID-19 pandemic and people’s motivations to seek help.
Building for the Future
In a recent interview with Informa Connect's Xconomy, our Chief Operating Officer, Blair Jackson, discusses our ambitions and our evolving strategy in neuroscience and oncology.
Alkermes at ASCO
We hosted a webcast in June 2021 with expert oncologists and ARTISTRY clinical program investigators to review data updates presented at the 2021 ASCO Annual Meeting.
HBA Rising Star 2021
We’re proud to recognize Joyanna Wesche-Blake, Senior Director of IT, as our 2021 Healthcare Businesswomen’s Association (HBA) Rising Star – a testament to her leadership and commitment to excellence.
Investor R&D Day
We hosted a virtual Investor Day in March 2021 to discuss our research and development strategy and portfolio, including updates from our nemvaleukin alfa development program in immuno-oncology and ne
In the News
In this “The Medicine Maker” article, our Chief Operating Officer, Blair Jackson, discusses how to determine corporate readiness when exploring a new therapeutic area and reflects on Alkermes' entry i